臨床外科77巻2号

2022年02月発行

特集 ガイドラインには書いていない 大腸癌外科治療のCQ—妥当な治療と適応を見直そう

TNM以外で本当に臨床的に有用な大腸癌の予後因子はあるのか—炎症性マーカー，栄養指標および遺伝子を用いた大腸癌治癒切除後予後因子の検討

著者： 端山軍¹ 松田圭二¹ 橋口陽二郎¹

所属機関： ¹帝京大学外科学講座

ページ範囲：P.136 - P.141

【ポイント】
◆炎症性マーカーにおいて，好中球/リンパ球比（NLR），血小板/リンパ球比（PLR），単球/リンパ球比（MLR）が再発予測因子として有用であった．
◆栄養指標の中でPrognostic Nutritional Index（PNI），Glasgow Prognostic Score（GPS），Controlling Nutritional Status（CONUT）スコアで再発率の予測因子として有用性を比較したところ，CONUTスコアが一番有用であった．
◆RAS変異，BRAF変異ではKRAS遺伝子変異が予後予測因子であった．

参考文献

1）Forrest LM, McMillan DC, McArdle CS, et al：Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89：1028-1030, 2003

2）Ying HQ, Deng QW, He BS, et al：The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol 31：305, 2014

3）Hayama T, Hashiguchi Y, Okada Y, et al：Significance of the 7th postoperative day neutrophil-to-lymphocyte ratio in colorectal cancer. Int J Colorectal Dis 35：119-124, 2020

4）Ishizuka M, Nagata H, Takagi K, et al：Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 246：1047-1051, 2007

5）Roxburgh CS, Platt JJ, Leitch EF, et al：Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol 18：997-1005, 2011

6）Hayama T, Ozawa T, Okada Y, et al：The pretreatment Controlling Nutritional Status（CONUT）score is an independent prognostic factor in patients undergoing resection for colorectal cancer. Sci Rep 10：13239, 2020

7）Andreyev HJ, Norman AR, Cunningham D, et al：Kirsten ras mutations in patients with colorectal cancer：the multicenter “RASCAL” study. J Natl Cancer Inst 90：675-684, 1998

8）Hayama T, Hashiguchi Y, Okamoto K, et al：G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer. Int J Colorectal Dis 34：1491-1496, 2019

9）Benson AB 3rd, Schrag D, Somerfield MR, et al：American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. Journal of Clinical Oncology 22：3408-3419, 2004

10）Argilés G, Tabernero J, Labianca R, et al：Localised colon cancer：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31：1291-1305, 2020

11）National Comprehensive Cancer Network（NCCN）：NCCN clinical practice guidelines in oncology〔https://www.nccn.org/professionals/physician_gls〕（Accessed on May 06, 2021）．

12）Lu C, Gao P, Yang Y, et al：Prognostic evaluation of platelet to lymphocyte ratio in patients with colorectal cancer. Oncotarget 8：86287-86295, 2017

13）Mantovani A, Allavena P, Sica A, et la：Cancer-related inflammation. Nature 454：436-444, 2008

14）Xia LJ, Li W, Zhai JC, et al：Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1-2 rectal cancer. BMC Cancer 20：208, 2020

15）Tominaga T, Nonaka T, Hisanaga M, et al：Prognostic value of the preoperative prognostic nutritional index in oldest-old patients with colorectal cancer. Surg Today 50：449-459, 2020

16）Tokunaga R, Sakamoto Y, Nakagawa S, et al：CONUT：a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. Int J Colorectal Dis 32：99-106, 2017

17）Seligmann JF, Fisher D, Smith CG, et al：Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer：analysis from 2530 patients in randomised clinical trials. Ann Oncol 28：562-568, 2017

18）Lochhead P, Kuchiba A, Imamura Y, et al：Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105：1151-1156, 2013